Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,699 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.
Fischer L, Grieb N, Born P, Weiss R, Seiffert S, Boldt A, Fricke S, Franz P, Heyn S, Kubasch AS, Baber R, Weidner H, Wang SY, Bach E, Hoffmann S, Ussmann J, Kirchberg J, Hell S, Schwind S, Metzeler KH, Herling M, Jentzsch M, Franke GN, Sack U, Reiche K, Köhl U, Platzbecker U, Vucinic V, Merz M. Fischer L, et al. Among authors: wang sy. Leukemia. 2024 Feb;38(2):372-382. doi: 10.1038/s41375-023-02129-y. Epub 2024 Jan 6. Leukemia. 2024. PMID: 38184754 Free PMC article.
Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing.
Gerhardt F, Maier M, Liebert UG, Platzbecker U, Wang SY, Papp CP, Bock CT, Berg T, van Bömmel F. Gerhardt F, et al. Among authors: wang sy. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01525-19. doi: 10.1128/AAC.01525-19. Print 2019 Dec 20. Antimicrob Agents Chemother. 2019. PMID: 31685465 Free PMC article. No abstract available.
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
Holzhey T, Pönisch W, Wang SY, Holzvogt M, Holzvogt B, Andrea M, Zehrfeld T, Hammerschmidt D, Hoffmann FA, Becker C, Schwarzer A, Schwarz M, Schönfelder-Fricke U, Edelmann T, Braunert L, Franke GN, Jentzsch M, Schwind S, Bill M, Grimm J, Remane Y, Platzbecker U, Scholz M. Holzhey T, et al. Among authors: wang sy. J Cancer Res Clin Oncol. 2021 Aug;147(8):2349-2359. doi: 10.1007/s00432-020-03504-3. Epub 2021 Jan 12. J Cancer Res Clin Oncol. 2021. PMID: 33433659 Free PMC article.
Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation.
Wang SY, Thomassen K, Kurch L, Opitz S, Franke GN, Bach E, Platzbecker U, Kayser S. Wang SY, et al. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e579-e582. doi: 10.1016/j.clml.2021.02.008. Epub 2021 Mar 2. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33795208 No abstract available.
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study.
Wang SY, Holzhey T, Heyn S, Zehrfeld T, Fricke S, Hoffmann FA, Becker C, Braunert L, Edelmann T, Paulenz I, Hitzschke M, Flade F, Schwarzer A, Fenchel K, Franke GN, Vucinic V, Jentzsch M, Schwind S, Hell S, Backhaus D, Lange T, Niederwieser D, Scholz M, Platzbecker U, Pönisch W. Wang SY, et al. J Cancer Res Clin Oncol. 2023 Jul;149(7):3739-3752. doi: 10.1007/s00432-022-04184-x. Epub 2022 Aug 20. J Cancer Res Clin Oncol. 2023. PMID: 35987926 Free PMC article.
Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma.
Teipel R, Rieprecht S, Trautmann-Grill K, Röllig C, Klötzer C, Zimmer K, Rathaj G, Bach E, Brückner M, Heyn S, Wang SY, Jentzsch M, Schwind S, Kretschmann T, Egger-Heidrich K, Remane Y, Franke GN, von Bonin M, Bornhäuser M, Platzbecker U, Hölig K, Merz M, Vučinić V. Teipel R, et al. Among authors: wang sy. Transfusion. 2023 Nov;63(11):2131-2139. doi: 10.1111/trf.17566. Epub 2023 Oct 18. Transfusion. 2023. PMID: 37850414
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma.
Rade M, Grieb N, Weiss R, Sia J, Fischer L, Born P, Boldt A, Fricke S, Franz P, Scolnick J, Venkatraman L, Xu S, Kloetzer C, Heyn S, Kubasch AS, Baber R, Wang SY, Bach E, Hoffmann S, Ussmann J, Schetschorke B, Hell S, Schwind S, Metzeler KH, Herling M, Jentzsch M, Franke GN, Sack U, Köhl U, Platzbecker U, Reiche K, Vucinic V, Merz M. Rade M, et al. Among authors: wang sy. Nat Cancer. 2024 Apr 19. doi: 10.1038/s43018-024-00763-8. Online ahead of print. Nat Cancer. 2024. PMID: 38641734
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.
Ocio EM, Perrot A, Bories P, San-Miguel JF, Blau IW, Karlin L, Martinez-Lopez J, Wang SY, Bringhen S, Marcatti M, Mateos MV, Rodriguez-Otero P, Oliva S, Nogai A, Le Roux N, Dong L, Macé S, Gassiot M, Fitzmaurice T, Oprea C, Moreau P. Ocio EM, et al. Among authors: wang sy. Leukemia. 2023 Jul;37(7):1521-1529. doi: 10.1038/s41375-023-01936-7. Epub 2023 Jun 14. Leukemia. 2023. PMID: 37316728 Free PMC article. Clinical Trial.
3,699 results